WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 15-Jul-2014 (Data received as of 8-Jul-2014)
Next overall update Fall 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 53'6701 Infant (under 12 months) mortality rate: 62
GDP / capita (US$): 53'1431 Child (under 5 years) mortality rate: 72

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 320'051  317'505  314'912  312'247  309'492  284'594  254'507  230'176 
Births 4'230  4'226  4'229  4'236  4'244  4'046  4'036  3'484 
Surviving infants 4'204  4'199  4'202  4'209  4'216  4'017  3'997  3'439 
Pop. less than 5 years 20'785  20'623  20'512  20'441  20'460  19'460  19'160  16'685 
Pop. less than 15 years 62'561  62'301  62'095  61'947  61'813  60'760  55'184  52'021 
Female 15-49 years 74'735  74'740  74'728  74'673  74'661  72'685  67'154  59'523 

Number of reported case

(Click for retrospective incidence data for United States of America (the))
Diphtheria
Japanese encephalitis
Measles 55  222  63  71  85  27'786  13'506 
Mumps 229  404  2'611  1'991  323 
Pertussis 47'693  18'610  27'410  7'867  4'570  1'730 
Polio*
Rubella 176 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total) 37  37  26  18  35  64  95 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for United States of America (the))
Vaccine year result method % card seen                                                
BCG         
DTP1          98  98  100 
DTP3          94  96  95  95  95  94  96 
HepB_BD          72  69  61  64 
HepB3          90  91  92  91  92  90 
Hib3          93  94  90  88  84  93 
JapEnc         
MCV          91  92  92  90  90  91  86 
MCV2         
PCV1          97  97 
PCV3          92  94  93  92  93 
Pol3          93  94  93  94  93  90  95 
Rota1          83  74 
Rota_last          69  44  59  58  44 
Rubella1          91  92  90 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for United States of America (the))
DTP1 98  98  98  98  98  99  96  98 
DTP3 94  96  95  95  95  94  90  96 
HepB3 90  91  92  92  92  90 
HepB_BD 72  69  67  64  61 
Hib3 93  94  90  90  84  93 
MCV 91  92  92  92  90  91  90  86 
MCV2
PCV3 92  94  93  93  93 
Pol3 93  94  93  93  93  90  85  95 
Rota_last 69  64  59  59  44 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaP 2, 4, 6, 15-18 months; 4-6 years; Yes
DTaPHepBIPV 2, 4, 6 months;
DTaPHibIPV 2, 4, 6, 15-18 months;
DTaPIPV 4-6 years (x2);
HPV 11-12 years; +1-2, +6 months; Yes
HepA 12-23 months; + 6-18 months; Yes
HepB birth; 1-2, 6-18 months; Yes And adults at risk
Hib 2, 4, 6, 12-15 months; Yes depending on the brand administered, a 3rd dose at 6 months may not be needed
IPV 2, 4, 6-18 months; 4-6 years; Yes
Influenza 6-23 months; > 50 years; Yes and risk groups
MMR 12-15 months; 4-6 years; Yes
MenACWY 11-12 years;
Pneumo_conj 2, 4, 6, 12-15 months; Yes
Pneumo_ps 65 years; Yes and adults 19-64 with certain high risk conditions
Rotavirus 2, 4, 6 months; Yes or 2, 4 months depending on the vaccine
Td every 10 years
Tdap 11-12 years; Yes
Varicella 12-15 months; 4-6 years; Yes

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR              
What years does the MYP cover? number   Yes           
Nº of districts with microplans that include activities to raise immunization coverage number              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes      Yes       

System performance

Total Nº districts in country number              
Nº districts with DTP3 coverage >=80% number        
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number          
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND              
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR   Yes           

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100%              

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.